These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 28139627

  • 1. [Device-aided therapies in advanced Parkinson's disease].
    Timofeeva AA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):54-60. PubMed ID: 28139627
    [Abstract] [Full Text] [Related]

  • 2. The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
    Dijk JM, Espay AJ, Katzenschlager R, de Bie RMA.
    J Parkinsons Dis; 2020; 10(s1):S65-S73. PubMed ID: 32651333
    [Abstract] [Full Text] [Related]

  • 3. Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.
    Richter D, Bartig D, Jost W, Jörges C, Stumpe B, Gold R, Krogias C, Tönges L.
    J Neural Transm (Vienna); 2019 Jul; 126(7):879-888. PubMed ID: 31222604
    [Abstract] [Full Text] [Related]

  • 4. [Treatment possibilities in advanced Parkinson's disease].
    Takáts A, Nagy H, Radics P, Tóth A, Tamás G.
    Ideggyogy Sz; 2013 Nov 30; 66(11-12):365-71. PubMed ID: 24555235
    [Abstract] [Full Text] [Related]

  • 5. Use of advanced therapies for Parkinson's disease in Norway.
    Ezat B, Pihlstrøm L, Aasly J, Tysnes OB, Egge A, Dietrichs E.
    Tidsskr Nor Laegeforen; 2017 May 30; 137(9):619-623. PubMed ID: 28468476
    [Abstract] [Full Text] [Related]

  • 6. Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.
    Antonini A, Nitu B.
    J Neural Transm (Vienna); 2018 Aug 30; 125(8):1131-1135. PubMed ID: 30006821
    [Abstract] [Full Text] [Related]

  • 7. Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia.
    Williams DR, Evans AH, Fung VSC, Hayes M, Iansek R, Kimber T, O'Sullivan JD, Sue CM.
    Intern Med J; 2017 Oct 30; 47(10):1107-1113. PubMed ID: 28195385
    [Abstract] [Full Text] [Related]

  • 8. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach.
    Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, Onuk K, Odin PLA.
    Curr Med Res Opin; 2018 Dec 30; 34(12):2063-2073. PubMed ID: 30016901
    [Abstract] [Full Text] [Related]

  • 9. Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.
    Volkmann J, Albanese A, Antonini A, Chaudhuri KR, Clarke CE, de Bie RM, Deuschl G, Eggert K, Houeto JL, Kulisevsky J, Nyholm D, Odin P, Østergaard K, Poewe W, Pollak P, Rabey JM, Rascol O, Ruzicka E, Samuel M, Speelman H, Sydow O, Valldeoriola F, van der Linden C, Oertel W.
    J Neurol; 2013 Nov 30; 260(11):2701-14. PubMed ID: 23287972
    [Abstract] [Full Text] [Related]

  • 10. [Selection of the optimal device-aided therapy in Parkinson's disease].
    Kovács N, Aschermann Z, Juhász A, Harmat M, Pintér D, Janszky J.
    Ideggyogy Sz; 2019 Jan 30; 72(1-2):5-11. PubMed ID: 30785241
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
    Elia AE, Dollenz C, Soliveri P, Albanese A.
    Eur J Neurol; 2012 Jan 30; 19(1):76-83. PubMed ID: 21645174
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Adjunctive Therapies in Parkinson's Disease: How to Choose the Best Treatment Strategy Approach.
    Fabbri M, Rosa MM, Ferreira JJ.
    Drugs Aging; 2018 Dec 30; 35(12):1041-1054. PubMed ID: 30318555
    [Abstract] [Full Text] [Related]

  • 17. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
    Wirdefeldt K, Odin P, Nyholm D.
    CNS Drugs; 2016 May 30; 30(5):381-404. PubMed ID: 27138916
    [Abstract] [Full Text] [Related]

  • 18. The role of subcutaneous infusion of apomorphine in Parkinson's disease.
    Wenzel K, Homann CN, Fabbrini G, Colosimo C.
    Expert Rev Neurother; 2014 Jul 30; 14(7):833-43. PubMed ID: 24917215
    [Abstract] [Full Text] [Related]

  • 19. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
    Othman AA, Chatamra K, Mohamed ME, Dutta S, Benesh J, Yanagawa M, Nagai M.
    Clin Pharmacokinet; 2015 Sep 30; 54(9):975-84. PubMed ID: 25875940
    [Abstract] [Full Text] [Related]

  • 20. Device-aided therapies for advanced Parkinson disease: insights from an international survey.
    Marsili L, Bologna M, Miyasaki JM, Colosimo C.
    Neurol Sci; 2021 Jul 30; 42(7):2961-2964. PubMed ID: 33550525
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.